The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil-to-lymphocyte ratio as a predictor of response and toxicity in T-cell engager therapy for solid tumors.
 
Aishwarya Nene
No Relationships to Disclose
 
Mark Bridge
No Relationships to Disclose
 
Rahul Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; Curio Science; EcoR1 Capital; Exelixis; Flare Therapeutics; Guidepoint Inc; Harpoon therapeutics; Janssen; Merck; MJH Life Sciences; Novartis; PCCTC; Pfizer; Research to Practice; Slingshot Insights; Tersera; Washington Research Foundation
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
David Oh
Consulting or Advisory Role - Maze Therapeutics; Revelation Partners
Research Funding - Allogene Therapeutics (Inst); Amgen (Inst); Merck (Inst); Nutcracker Therapeutics, Inc. (Inst); PACT Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Poseida Therapeutics (Inst); Roche/Genentech (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - DAVA Oncology; Poseida Therapeutics; Roche/Genentech
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; BioAtla; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma; Therapaint
Consulting or Advisory Role - Abbvie; Actym Therapeutics; BioAtla; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; ImmunoGenesis; Innovent Biologics; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Bridget Keenan
Employment - Astellas Pharma (I)
Consulting or Advisory Role - Agenus; Cartography; Regeneron
Research Funding - Antengene (Inst); Apexigen (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); Innovative Cellular Therapeutics Co (Inst); Partner Therapeutics (Inst); Regeneron (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Genentech/Roche